Skip to content
Back to Investors
Lakestar

Lakestar

Venture Capital

Lakestar recently closed a $300m fund named Resilience I focused on defence and dual-use technology, with a portfolio including Helsing, Tekever, ARX Robotics, and Isar Aerospace.


Recent investments

Seed
£5.6M

The funding round was led by HV Capital and Lakestar to support the development of next generation payment systems.

"We believe payments is entering a new paradigm where traditional finance is meeting the Web3 future of finance, and that these will coexist for years to come. The challenge and the opportunity right now is to bridge these very different worlds, and build the interoperability to enable choice across the three generational payments use cases, from cards to open banking to crypto and everything in between."
— David Nunn, Founder & CEO
Seed
£1.6M

The seed round was backed by angel investors and venture capital firms including Lakestar, SIX Fintech Ventures, and JME Ventures.

"Small businesses are the lifeblood of our economy, yet many are struggling to get back on their feet after the pandemic. We’re on a mission to support them getting paid on time and, by digitising the payment process, stop the time they waste chasing and managing payments; ultimately supporting a stronger cash flow and meaning they can survive and thrive."
— Pete Bailey, Co-founder and Chief Product Officer
Series B
£27.5M

The Series B round was led by Lakestar with backing from institutional investors and venture funds to support team growth and product expansion.

"accuRx’s product has reinvigorated communication with our patients, enabling a better relationship between GPs and patients, which has ultimately led to better care provision. Our patients now have the confidence that they’re getting speedy and accurate responses from our team, and the use of regular Florey questionnaires to gather more information from our patients has been transformative for clinical record keeping and the care we provide. We’re thrilled that accuRx has received funding which will enable it to expand its primary care product set, some of which we’re trialling at the moment. We’re also excited about accuRx’s progress into secondary care as better interaction between primary and secondary care is a huge step forward for safer and more effective patient care."
— David Triska, GP Partner
Series B
£37.4M

Sapphire Ventures led the Series B round with participation from existing investors Lakestar, HV Capital and Latitude.

"We are delighted with this strategic investment, demonstrating Yapily’s position at the heart of disrupting global financial infrastructure. As we got to know Sapphire Ventures, it was clear that they are hugely supportive of our strategic approach and share our vision of open finance. Open Banking infrastructure is fundamental to how data and payments move between organisations worldwide, and it will shift the power to consumers for years to come. We are only starting to scratch the surface of what’s possible."
— Stefano Vaccino, CEO and Founder
Seed
£2.6M

The seed financing was led by Lakestar and Outward VC to support international expansion and product development.

"Finding your costs are so much larger is shocking, but also something to be celebrated. These incremental costs were always there, they just weren’t exposed, and now you can identify those and bring about change. You can’t manage what you don’t measure."
— Christopher Sier, CEO